Literature DB >> 8420680

Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991.

M S Piver1, T R Baker, M F Jishi, A M Sandecki, Y Tsukada, N Natarajan, C J Mettlin, C A Blake.   

Abstract

BACKGROUND: Because of the small number of cases (five) reported between 1929 and 1969 and a significant increase reported in the decade of the 1970s, the Familial Ovarian Cancer Registry was established in 1981 to study the occurrence of familial ovarian cancer in the United States.
METHODS: Any woman (with or without ovarian cancer herself) who contacted the Registry and demonstrated a familial history of ovarian cancer was added to the Registry as an index case.
RESULTS: From 1981 through May 31, 1991, 658 families for a total of 1568 cases of familial ovarian cancer were accessioned into the Registry. Of the 219 mothers and 251 daughters with familial ovarian cancer, the mean (58.5 years) and median (57.0 years) age at diagnosis of the mothers was significantly older than the mean (49.8 years) and median (49.0 years) ages of their daughters with ovarian cancer. Significantly more index cases without ovarian cancer had used oral contraceptives as compared to index cases with ovarian cancer (P < 0.001). Significantly more index cases with ovarian cancer used other estrogens as compared to index cases without ovarian cancer (P < 0.001). The Registry cases exhibited a higher proportion of serous adenocarcinoma, poorly differentiated adenocarcinoma, borderline carcinoma, and gonadoblastoma as compared to the 1978 SEER data. Mother and a minimum of one daughter was the most common relationship and was represented in 49.5% of the families with familial ovarian cancer. Sister-sister relationships were the second most frequent and accounted for 38.5% of the 658 families.
CONCLUSIONS: Familial ovarian cancer occurs most frequently in mother-daughter relationships followed by sister-sister and appears to be an autosomal dominant inheritance with variable penetrance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420680     DOI: 10.1002/cncr.2820710214

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Forth nightly review: hereditary ovarian carcinoma.

Authors:  L Kasprzak; W D Foulkes; A N Shelling
Journal:  BMJ       Date:  1999-03-20

2.  Can you screen for ovarian cancer?

Authors:  M L Hicks; G Parham
Journal:  J Natl Med Assoc       Date:  1995-02       Impact factor: 1.798

Review 3.  Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.

Authors:  R E Heisey; J C Carroll; E Warner; D R McCready; V Goel
Journal:  Can Fam Physician       Date:  1999-01       Impact factor: 3.275

4.  Family history in ovarian cancer referral population.

Authors:  L A Berg; S Robert Young; K A Brooks; A M Davis; S Terry Smith
Journal:  J Genet Couns       Date:  1996-03       Impact factor: 2.537

5.  An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.

Authors:  S A Narod; D Ford; P Devilee; R B Barkardottir; H T Lynch; S A Smith; B A Ponder; B L Weber; J E Garber; J M Birch
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

6.  Familial cluster of ovarian small cell carcinoma: a new mendelian entity?

Authors:  M Longy; C Toulouse; P Mage; J Chauvergne; M Trojani
Journal:  J Med Genet       Date:  1996-04       Impact factor: 6.318

7.  Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.

Authors:  Ian Solsky; Jinbo Chen; Timothy R Rebbeck
Journal:  Gynecol Oncol       Date:  2020-01-07       Impact factor: 5.304

8.  Segregation analysis of epithelial ovarian cancer in Finland.

Authors:  A Auranen; L Iselius
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

9.  Cancer incidence in the first-degree relatives of ovarian cancer patients.

Authors:  A Auranen; E Pukkala; J Mäkinen; R Sankila; S Grénman; T Salmi
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.